Seagen and genmab present first data on tisotumab vedotin (tivdak®) in patients with head and neck squamous cell carcinoma

Bothell, wash., & copenhagen, denmark--(business wire)--seagen inc. (nasdaq: sgen) and genmab a/s (nasdaq: gmab) will present preliminary data from the innovatv 207 global, open-label, multicenter phase 2 trial of tisotumab vedotin (tivdak®) as a monotherapy in patients with squamous cell carcinoma of the head and neck (scchn) who experienced disease progression on or after a first-line platinum-containing regimen and a checkpoint inhibitor. early results showed tisotumab vedotin demonstrated a
SGEN Ratings Summary
SGEN Quant Ranking